newsfilter
← Earnings
Earnings Releases·

Aclaris Therapeutics — Third Quarter 2026 Earnings Summary

Aclaris Therapeutics reported a net loss of $18.5 million for the third quarter of 2026, driven by increased research and development expenses related to ATI-052 and ATI-9494. The company announced positive primary analysis results from Phase 1b proof-of-concept trials for ATI-052 in atopic dermatitis and asthma, showing rapid improvements in skin symptoms and lung function. Aclaris plans to prioritize the development of ATI-052 in eosinophilic esophagitis and expects to initiate a Phase 2b trial for modzatinib in lichen planus during the fourth quarter of 2026. Additionally, the company raised $50.0 million in October 2026, extending its cash runway to fund operations through the first half of 2029.

Company
ACLARIS THERAPEUTICS INC
Sector
Healthcare
Industry
Diagnostics & Research